Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.
- Published In:
- International journal of clinical pharmacy (2026)
- Authors:
- Seijas-Amigo, Jose, Salgado-Barreira, Ángel, Rodriguez-Penas, Diego, Cardeso-Paredes, Begoña, Ribeiro-Ferreiro, Marta, Rodriguez-Mañero, Moisés, Gonzalez-Juanatey, Jose Ramon
- Database ID:
- RPEP-16085
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16085APA
Seijas-Amigo, Jose; Salgado-Barreira, Ángel; Rodriguez-Penas, Diego; Cardeso-Paredes, Begoña; Ribeiro-Ferreiro, Marta; Rodriguez-Mañero, Moisés; Gonzalez-Juanatey, Jose Ramon. (2026). Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.. International journal of clinical pharmacy. https://doi.org/10.1007/s11096-026-02099-y
MLA
Seijas-Amigo, Jose, et al. "Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.." International journal of clinical pharmacy, 2026. https://doi.org/10.1007/s11096-026-02099-y
RethinkPeptides
RethinkPeptides Research Database. "Comparative pharmacovigilance analysis of suicidality-relate..." RPEP-16085. Retrieved from https://rethinkpeptides.com/research/seijas-amigo-2026-comparative-pharmacovigilance-analysis-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.